Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34474845 | 0.73 | BUB1 (0.34) | BUB1 | |
| SCHEMBL33526452 | 0.69 | MAOA (0.31) | MAOAMAOB | |
| SCHEMBL33526277 | 0.68 | MAOA (0.36) | MAOAMAOB | |
| SCHEMBL4063497 | 0.67 | KDM4E (0.44) | MAOAMAOBALDH1A1KDM4EHPGD | |
| SCHEMBL15466341 | 0.66 | MAOA (0.41) | MAOAMAOBALDH1A1DYRK1ADYRK2 | |
| SCHEMBL4066514 | 0.65 | GAA (0.43) | MAOAMAOBALDH1A1KDM4EHPGD | |
| SCHEMBL4070347 | 0.65 | GAA (0.43) | MAOAMAOBALDH1A1KDM4EHPGD | |
| SCHEMBL4065469 | 0.65 | ALDH1A1 (0.43) | MAOAMAOBALDH1A1KDM4EHPGD | |
| SCHEMBL4072395 | 0.64 | NPC1 (0.39) | MAOAMAOBALDH1A1KDM4EHPGD | |
| SCHEMBL4067369 | 0.63 | MAOA (0.35) | MAOAMAOBALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091048-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GPR119 | RIPK1 3681/4885MAOA 3712/4885MAOB 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.